This study is designed to determine if the use of atorvastatin (Lipitor), a member of the HMG coA reductase inhibitor class of drugs referred to as statins, will reduce cardiovascular outcomes ( mortality - myocardial infarction - stroke ) when given in high doses in comparative standard doses in the perioperative period of major vascular surgery. Abdominal aortic aneurysm , Carotid endarterectomy , Revascularization of lower limbs
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
100
Atorvastatin 80 mg; Use Atorvastatin for 60 days , and the vascular surgery will be made between day-7 and day-60
Atorvastatin 20 mg; Use Atorvastatin for 60 days , and the vascular surgery will be made between day-7 and day-60
Clinics Hospital - State University Campinas
Campinas, São Paulo, Brazil
mortality ; myocardial infarction ; stroke
Time frame: within 90 days after surgery
Change and percent change from baseline to the surgery of treatment for LDL-C, HDL-C, TC, and TG for subjects
Time frame: within 24h before surgery
Change and percent change from baseline to the surgery of treatment for hs-CRP
Time frame: within 24h before surgery
Safety of atorvastatin through laboratory assessment
Time frame: within 24h before surgery
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.